There were 41 new drug approvals by the US Food and Drug Administration (FDA) in 2014, the highest number since 1996, when a record 53 new drugs were approved. This number is significantly higher than the 27 drugs approved in 2013. As has been the case for the past 3 years, specialty and orphan drugs dominated the approval list.
The high clinical and economic burdens associated with cardiometabolic conditions, including cardiovascular disease, diabetes, and obesity, in the United States present ongoing challenges for patients, providers, payers, drug manufacturers, and the entire healthcare system.
The outlook for cardiometabolic health remains suboptimal in 2013, despite considerable awareness of the health consequences and the associated costs of cardiometabolic risk factors, including cardiovascular disease, diabetes, dyslipidemia, hypertension, and obesity. There is not much that has not been said about these top killers of Americans. Yet despite all the research and the published literature, new treatments, and well-documented high morbidity and mortality associated with heart disease, type 2 diabetes, and obesity, the incidence of each of these conditions continues to climb.
Researchers have made great strides in unlocking the biology of cancer, especially on the molecular and immunologic levels, and this is rapidly being translated into new therapies. With more than 900 oncology compounds currently in development,1 advancements in molecular sequencing, and new diagnostic modalities, cancer care has become a major focus for investment and research, and with it come challenges and opportunities.
Cancer has always been a devastating and deadly disease. Unlike many other illnesses, it does not discriminate among populations, and it spares neither young nor old. As our population ages, and the menu for diagnostic tools and treatments becomes more expansive and sophisticated, cancer has been evolving as an increasingly dominant disease for research and discussion. Only 30 years ago, our ability to differentiate subclasses, subtypes, and even the stage of cancer was significantly more limited than it is today.
Results 1 - 9 of 9